Ceritinib
Sign in to save this workspacePrimary targets: ALK · FDA status: FDA Approved
Selectivity scorecard
KISS
95.44
Gini
0.618
CATDS
0.014
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Ceritinib. Strongest target: FES_FPS at 99.8% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | FES_FPS | 99.8% | 0.3% |
| 2 | STK22D_TSSK1 | 99.7% | 0.3% |
| 3 | LRRK2 | 99.4% | 0.6% |
| 4 | IRR_INSRR | 98.9% | 1.1% |
| 5 | FER | 98.4% | 1.6% |
| 6 | ALK | 98.3% | 1.7% |
| 7 | IGF1R | 98.1% | 1.9% |
| 8 | IR | 97.8% | 2.2% |
| 9 | ROS_ROS1 | 97.7% | 2.3% |
| 10 | TNK1 | 97.3% | 2.7% |
| 11 | TYK1_LTK | 97.3% | 2.7% |
| 12 | ACK1 | 97.2% | 2.8% |
| 13 | FAK_PTK2 | 96.4% | 3.6% |
| 14 | MYO3B | 94.4% | 5.6% |
| 15 | CAMKK2 | 92.7% | 7.3% |
| 16 | CLK1 | 92.1% | 7.9% |
| 17 | CLK2 | 91.1% | 8.9% |
| 18 | PHKG1 | 90.1% | 9.9% |
| 19 | PYK2 | 89.7% | 10.3% |
| 20 | STK32B_YANK2 | 89.3% | 10.7% |
Selectivity landscape
Where Ceritinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Ceritinib.
Atlas insights for Ceritinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target3%
Off-target97%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 1150.87 | |
| ALLOGRAFT_REJECTION | 3699.17 | |
| ANDROGEN_RESPONSE | 1336.08 | |
| ANGIOGENESIS | 854.18 | |
| APICAL_JUNCTION | 4242.72 | |
| APICAL_SURFACE | 456.58 | |
| APOPTOSIS | 3604.64 | |
| BILE_ACID_METABOLISM | 727.17 | |
| CHOLESTEROL_HOMEOSTASIS | 591.22 | |
| COAGULATION | 544.16 | |
| COMPLEMENT | 2419.87 | |
| DNA_REPAIR | 1000.78 | |
| E2F_TARGETS | 3452.41 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 1092.49 | |
| ESTROGEN_RESPONSE_EARLY | 2299.43 | |
| ESTROGEN_RESPONSE_LATE | 2198.60 | |
| FATTY_ACID_METABOLISM | 414.12 | |
| G2M_CHECKPOINT | 3258.07 | |
| GLYCOLYSIS | 1860.37 | |
| HEDGEHOG_SIGNALING | 549.19 | |
| HEME_METABOLISM | 1092.43 | |
| HYPOXIA | 2508.76 | |
| IL2_STAT5_SIGNALING | 1415.77 | |
| IL6_JAK_STAT3_SIGNALING | 2257.31 | |
| INFLAMMATORY_RESPONSE | 2431.96 | |
| INTERFERON_ALPHA_RESPONSE | 339.56 | |
| INTERFERON_GAMMA_RESPONSE | 3095.51 | |
| KRAS_SIGNALING_DN | 951.33 | |
| KRAS_SIGNALING_UP | 1342.19 | |
| MITOTIC_SPINDLE | 3460.05 | |
| MTORC1_SIGNALING | 2293.50 | |
| MYC_TARGETS_V1 | 2209.88 | |
| MYC_TARGETS_V2 | 582.63 | |
| MYOGENESIS | 2102.50 | |
| NOTCH_SIGNALING | 224.56 | |
| OXIDATIVE_PHOSPHORYLATION | 576.84 | |
| P53_PATHWAY | 2033.40 | |
| PANCREAS_BETA_CELLS | 163.26 | |
| PEROXISOME | 602.18 | |
| PI3K_AKT_MTOR_SIGNALING | 4537.83 | |
| PROTEIN_SECRETION | 1134.27 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 153.45 | |
| SPERMATOGENESIS | 948.11 | |
| TGF_BETA_SIGNALING | 873.00 | |
| TNFA_SIGNALING_VIA_NFKB | 2516.03 | |
| UNFOLDED_PROTEIN_RESPONSE | 989.95 | |
| UV_RESPONSE_DN | 2313.53 | |
| UV_RESPONSE_UP | 2075.05 | |
| WNT_BETA_CATENIN_SIGNALING | 1407.58 | |
| XENOBIOTIC_METABOLISM | 1161.43 |
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.867 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.849 |
| SRR23303752 | — | 0.834 |
| R247 | — | 0.830 |
| SRR12202498 | — | 0.830 |
Annotations
Sign in to read and post annotations.
Loading…